Coronavirus Notebook: Leading Vaccines Near Approval, EU Signs More Advance Purchase Deals
Developers Are Under Pressure To Share Their IP And Reveal Costs
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
You may also be interested in...
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.